BACKGROUND: Genome-wide association studies have established 11 genes for late-onset Alzheimer's disease (AD). We investigated whether these genes jointly affect cognition in a nondemented population and improve prediction of AD. METHODS: In 5171 nondemented people (age 45-99 years) from the population-based Rotterdam Study, we genotyped APOE-ε4 and single nucleotide polymorphisms from the genes CLU, PICALM, BIN1, CR1, ABCA7, MS4A6A, MS4A4E, CD2AP, EPHA1, and CD33. We constructed a genetic risk score by adding the risk alleles per individual weighted by the reported effect sizes. All people underwent cognitive testing. With linear regression we investigated the relationship between the genetic risk score and cognition, with and without APOE. In a subcohort, with more than 10 years of follow-up, we assessed whether the risk score predicted AD. RESULTS: The genetic risk score was primarily associated with memory (standardized difference [95% confidence interval] per SD increase in genetic risk score: -.05[-.07; -.02], p = 1.5 * 10(-4)). This association attenuated when APOE was excluded from the genetic risk score (-.03[-.05; .00], p = .047) and would not survive a multiple-testing correction. Similarly, we found that although the genetic risk score without APOE was associated with the development of AD (p = .010), it only marginally improved prediction of AD beyond age, sex, APOE (area under the curve: .8159 vs. .8148). CONCLUSIONS: In nondemented people, there is only a marginal joint effect of AD genes on memory independent from APOE. Moreover, although associated with AD, these genes jointly hardly improve prediction of AD.
BACKGROUND: Genome-wide association studies have established 11 genes for late-onset Alzheimer's disease (AD). We investigated whether these genes jointly affect cognition in a nondemented population and improve prediction of AD. METHODS: In 5171 nondemented people (age 45-99 years) from the population-based Rotterdam Study, we genotyped APOE-ε4 and single nucleotide polymorphisms from the genes CLU, PICALM, BIN1, CR1, ABCA7, MS4A6A, MS4A4E, CD2AP, EPHA1, and CD33. We constructed a genetic risk score by adding the risk alleles per individual weighted by the reported effect sizes. All people underwent cognitive testing. With linear regression we investigated the relationship between the genetic risk score and cognition, with and without APOE. In a subcohort, with more than 10 years of follow-up, we assessed whether the risk score predicted AD. RESULTS: The genetic risk score was primarily associated with memory (standardized difference [95% confidence interval] per SD increase in genetic risk score: -.05[-.07; -.02], p = 1.5 * 10(-4)). This association attenuated when APOE was excluded from the genetic risk score (-.03[-.05; .00], p = .047) and would not survive a multiple-testing correction. Similarly, we found that although the genetic risk score without APOE was associated with the development of AD (p = .010), it only marginally improved prediction of AD beyond age, sex, APOE (area under the curve: .8159 vs. .8148). CONCLUSIONS: In nondemented people, there is only a marginal joint effect of AD genes on memory independent from APOE. Moreover, although associated with AD, these genes jointly hardly improve prediction of AD.
Authors: Jessica R Marden; Elizabeth R Mayeda; Stefan Walter; Alexandre Vivot; Eric J Tchetgen Tchetgen; Ichiro Kawachi; M Maria Glymour Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: Mark T W Ebbert; Perry G Ridge; Andrew R Wilson; Aaron R Sharp; Matthew Bailey; Maria C Norton; JoAnn T Tschanz; Ronald G Munger; Christopher D Corcoran; John S K Kauwe Journal: Biol Psychiatry Date: 2013-08-13 Impact factor: 13.382
Authors: Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij Journal: Eur J Epidemiol Date: 2013-11-21 Impact factor: 8.082
Authors: Minerva M Carrasquillo; Julia E Crook; Otto Pedraza; Colleen S Thomas; V Shane Pankratz; Mariet Allen; Thuy Nguyen; Kimberly G Malphrus; Li Ma; Gina D Bisceglio; Rosebud O Roberts; John A Lucas; Glenn E Smith; Robert J Ivnik; Mary M Machulda; Neill R Graff-Radford; Ronald C Petersen; Steven G Younkin; Nilüfer Ertekin-Taner Journal: Neurobiol Aging Date: 2014-08-04 Impact factor: 4.673
Authors: Gabriëlla A M Blokland; Raquelle I Mesholam-Gately; Timothea Toulopoulou; Elisabetta C Del Re; Max Lam; Lynn E DeLisi; Gary Donohoe; James T R Walters; Larry J Seidman; Tracey L Petryshen Journal: Schizophr Bull Date: 2017-07-01 Impact factor: 9.306
Authors: Burcu F Darst; Rebecca L Koscik; Annie M Racine; Jennifer M Oh; Rachel A Krause; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Bradley T Christian; Barbara B Bendlin; Ozioma C Okonkwo; Kirk J Hogan; Bruce P Hermann; Mark A Sager; Sanjay Asthana; Sterling C Johnson; Corinne D Engelman Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Vincent Chouraki; Christiane Reitz; Fleur Maury; Joshua C Bis; Celine Bellenguez; Lei Yu; Johanna Jakobsdottir; Shubhabrata Mukherjee; Hieab H Adams; Seung Hoan Choi; Eric B Larson; Annette Fitzpatrick; Andre G Uitterlinden; Philip L de Jager; Albert Hofman; Vilmundur Gudnason; Badri Vardarajan; Carla Ibrahim-Verbaas; Sven J van der Lee; Oscar Lopez; Jean-François Dartigues; Claudine Berr; Philippe Amouyel; David A Bennett; Cornelia van Duijn; Anita L DeStefano; Lenore J Launer; M Arfan Ikram; Paul K Crane; Jean-Charles Lambert; Richard Mayeux; Sudha Seshadri Journal: J Alzheimers Dis Date: 2016-06-18 Impact factor: 4.472